UK firms Linklaters and Allen & Overy (A&O) are leading on UCB’s £1.5bn cash offer for Celltech – the UK’s largest biotech company – securing lead roles on the highest profile UK deal in the sector for years.
Linklaters partner Matthew Middleditch is leading the team advising UCB. The magic circle firm’s corporate partner Bridget Rentoul advised on US aspects, with Brussels corporate partner Didier Leclercq and London-based antitrust specialist Gerwin van Gerven advising on European Commission issues, alongside UCB’s group general counsel Jettie van Caenegem.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]